Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 3
1994 1
1996 1
1998 3
1999 1
2000 3
2001 2
2002 2
2003 2
2004 3
2005 6
2006 2
2007 3
2008 4
2009 1
2010 3
2011 3
2012 5
2013 2
2014 2
2015 2
2016 8
2017 13
2018 4
2019 7
2020 9
2021 11
2022 13
2023 8
2024 12
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, Martens FMAC, Steg PG, Visseren FLJ; REDUCE-IT Investigators. Burger PM, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):488-499. doi: 10.1093/ehjcvp/pvae030. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38678009 Free PMC article. Clinical Trial.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
Reply to: Posttransplant Hypertension Matters!
Wyld MLR, De La Mata NL, Masson P, O'Lone E, Kelly PJ, Webster AC. Wyld MLR, et al. Among authors: de la mata nl. Transplantation. 2021 Oct 1;105(10):e151. doi: 10.1097/TP.0000000000003832. Transplantation. 2021. PMID: 34591817 No abstract available.
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
Herrera-Hidalgo L, Muñoz P, Álvarez-Uría A, Alonso-Menchén D, Luque-Marquez R, Gutiérrez-Carretero E, Fariñas MDC, Miró JM, Goenaga MA, López-Cortés LE, Angulo-Lara B, Boix-Palop L, de Alarcón A; Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) Cohort Investigators. Herrera-Hidalgo L, et al. Int J Infect Dis. 2023 Dec;137:134-143. doi: 10.1016/j.ijid.2023.10.019. Epub 2023 Nov 4. Int J Infect Dis. 2023. PMID: 37926195 Free article.
A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study.
Palom-Grau C, Cuervo G, Muñoz P, Marín Arriaza M, Martínez-Sellés M, González-Ramallo V, de Alarcón A, Poyato-Borrego M, Rodríguez-García R, Rodríguez-Esteban MÁ, Fariñas MC, González-Rico C, Goenaga MÁ, Ojeda-Burgos G, Goikoetxea-Agirre AJ, Calderón-Parra J, López-Azor JC, García-Vázquez E, Loeches B, Quintana E, García de la Mària C, Llopis J, Miró JM; GAMES Investigators. Palom-Grau C, et al. J Am Coll Cardiol. 2025 Feb 4;85(4):305-318. doi: 10.1016/j.jacc.2024.09.027. Epub 2024 Nov 22. J Am Coll Cardiol. 2025. PMID: 39580721
135 results